reports
Diamond Hill Investment Group Inc: 1 director
A director at Diamond Hill Investment Group Inc sold/gave away 3,600 shares at 0.000USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
ANZ Group Holdings Ltd: 2 directors
Two Directors at ANZ Group Holdings Ltd bought/maiden bought 2,032 shares at between 28.740AUD and 28.810AUD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...
- Baptiste Lebacq
Vallourec : Continuing debt paydown/Q2 guidance below expectations
>EBITDA in line and debt reduction ahead of expectations - EBITDA at € 235m, -16% q-o-q and +27% y-o-y, in line with our forecasts at € 237m (consensus € 240m).Tubes EBITDA of € 220m, down 12% q-o-q and 21% y-o-y due to price reductions in the US and lower volumes, largely driven by the closure in GermanyMine and forests EBITDA of € 30m, - 29% q-o-q and 37% y-o-y as a result of lower sales volumes and a reduction in the non-cash effects for the revaluation o...
Commercial Real Estate Co: 1 director
A director at Commercial Real Estate Co bought 300,000 shares at 0.138KWD and the significance rating of the trade was 46/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Sdiptech AB : 2 directors
A director at Sdiptech AB sold 63,185 shares at 304.648SEK and the significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Green Landscaping Group AB: 2 directors
A director at Green Landscaping Group AB bought 130,000 shares at 81.000SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
- Cor Kluis
Aegon : New SBB, new good CFO, Q1 OCG and Solvency in line
>Conclusion: New SBB, new good CFO, OCG and Solvency in line - It was positive that Aegon announced a new SBB as that was not yet expected. Also positive is the appointment of a good new well known CFO Duncan Russell. Further the Q1 OCG capital generation and Solvency figures were in line. We keep our Outperform recommendation, and we see material future capital releases and return to come the coming years.Positive that new SBB is announced already - ...
Humacyte Inc: 1 director
A director at Humacyte Inc bought 100,000 shares at 6.675USD and the significance rating of the trade was 97/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- Johanna Jourdain
Elior : Encouraging H1 2024 results driving an upgrade to FY guidance ...
>H1 2023-24 results above expectations, with a significant beat on EBITA - Elior reported H1 2023-24 results (Oct. 2023 to March 2024) that beat expectations. Sales were € 3,123m, in line with the consensus at € 3,109m and up 26% on a reported basis. Organic growth was 5.9%, a shade above the consensus at 5.7% (ODDO BHF 6.5%e). We note an improvement in the retention rate to 92.3% (vs 91.3% in H1 2022-23), which remains impacted by voluntary contract exits (-1.3%). W...
IDEX Biometrics nomination committee proposal to 2024 annual general m...
IDEX Biometrics nomination committee proposal to 2024 annual general meeting Aligned with the restructuring of IDEX’s organization to consolidate development and business operations to be located primarily in the UK and the EU/EEA, and to reduce costs, the nomination committee proposes that IDEX also reduces the size of the board of directors to a total of three. The nomination committee proposes that the following board shall be elected: Mr. Morten Opstad to continue for the second year of his term, in the role of chair of the board. Ms. Annika Olsson and Ms. Adriana Saitta to continue ...
EQS-News: OCEANSIX FUTURE PATHS FAIT L’ACQUISITION D’ORIGINAL REPACK O...
EQS-News: oceansix future paths Ltd. / Mot-clé(s) : Autres OCEANSIX FUTURE PATHS FAIT L’ACQUISITION D’ORIGINAL REPACK OY 16.05.2024 / 10:00 CET/CEST Tel Aviv, Israël (15 mai 2024) – oceansix Future Paths Ltd. (« Oceansix » ou la « société »), une société leader en matière de solutions technologiques avancées de recyclage et de fabrication, présent à la Bourse de croissance TSX à Toronto (TSXV : CUSIP 001194828, OSIX), à New York (OTCQB : AKMYF) et à la Bourse de Francfort (WKN : A3EFB0, ISIN : IL0011948283, 5FC0), a le plaisir d’annoncer qu’elle a conclu aujourd’hui un accor...
EQS-News: Sartorius to advance drug discovery and manufacturing with A...
EQS-News: SARTORIUS AG / Key word(s): Alliance Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA (news with additional features) 16.05.2024 / 09:54 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, Germany, May 16, 2024 Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, and pre...
Deceuninck NV: 1 director
A director at Deceuninck NV sold 500,000 shares at 2.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Aurelien Sivignon
PulluP Entertainment : Lancement surprise d’une AK pouvant aller jusqu...
>AK jusqu’à 23 M€ avec suppression du DPS / décote de 3% - PulluP a annoncé cette nuit le lancement d’une AK de 17.5 M€ (i.e. 1.5m d’actions nouvelles soit 23% du K dilué) pouvant être porté jusqu’à 23 M€ en cas d’exercice intégral de la clause d’extension et de l’option de surallocation (i.e. 2m d’actions nouvelles soit 30% du K dilué).Le prix de souscription est 11.3 € par action traduisant une décote de 3% sur le dernier cours. Le DPS est supprimé avec un dél...
- Johanna Jourdain
Elior : Encouraging H1 2024 results driving an upgrade to FY guidance ...
>H1 2023-24 results above expectations, with a significant beat on EBITA - Elior reported H1 2023-24 results (Oct. 2023 to March 2024) that beat expectations. Sales were € 3,123m, in line with the consensus at € 3,109m and up 26% on a reported basis. Organic growth was 5.9%, a shade above the consensus at 5.7% (ODDO BHF 6.5%e). We note an improvement in the retention rate to 92.3% (vs 91.3% in H1 2022-23), which remains impacted by voluntary contract exits (-1.3%). W...
Share Buyback Transaction Details May 9 – May 15, 2024
Share Buyback Transaction Details May 9 – May 15, 2024 PRESS RELEASE Share Buyback Transaction Details May 9 – May 15, 2024 Alphen aan den Rijn - May 16, 2024 - Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 148,380 of its own ordinary shares in the period from May 9, 2024, up to and including May 15, 2024, for €21.7 million and at an average share price of €146.27. These repurchases are part of the share buyback program announced on February 21, ...
Europe’s Chemical Firms Seek Catalyst for Competitiveness
LONDON--(BUSINESS WIRE)-- A somewhat diluted European chemical industry is hoping that digital technology will provide the formula it needs to regain some of its strength in the global market, according to a new research report published today by Information Services Group () (Nasdaq: ), a leading global technology research and advisory firm. The 2024 ISG Provider Lens™ Chemical Industry Services and Solutions report for Europe finds that for a chemical industry plagued by a potent mix of environmental concerns, diminished demand and escalating costs, technology-driven innovation and digital...
Manhattan, pionnier sur l’utilisation de l’IA Générative pour la Suppl...
PARIS--(BUSINESS WIRE)-- (NASDAQ : MANH) annonce aujourd’hui la sortie conjointe de Manhattan Active® Maven, nouvelle solution de service client basée sur l’intelligence artificielle générative (GenAI), et de Manhattan Assist, qui vient enrichir toutes les solutions Manhattan Active avec des fonctionnalités GenAI. Avec l’intégration de cette technologie de dernière génération, Manhattan fait entrer les interactions client et l’usage de ses solutions dans une nouvelle ère. Manhattan Active Maven utilise la puissance de la technologie GenAI pour améliorer l’expérience client et réduire les co...
Manhattan Pioneers Use of GenAI in Supply Chain Commerce
LONDON--(BUSINESS WIRE)-- (NASDAQ: MANH) today announced Manhattan Active® Maven, a specialized Generative Artificial Intelligence (GenAI) solution built for customer service, along with Manhattan Assist, which adds cutting-edge GenAI capabilities to all Manhattan Active solutions. The company is applying this state-of-the-art technology to revolutionize consumer interactions, as well as enhancing how Manhattan's customers engage with their solutions. The new Manhattan Active Maven harnesses the power of GenAI technology to elevate customer experience while simultaneously reducing operation...
Verve Therapeutics Inc: 1 director
A director at Verve Therapeutics Inc bought 76,000 shares at 6.260USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.